Shares of Ernexa Therapeutics (NASDAQ: ERNA) experienced a significant surge on Wednesday, climbing approximately 60% after the company unveiled compelling preclinical data for its lead cell therapy candidate, ERNA-101, in ovarian cancer. The stock traded actively, with a session range between $3.70 and $7.66, reflecting heightened investor interest following the announcement.
Promising Preclinical Results
The Cambridge, Massachusetts-based biotechnology firm reported that ERNA-101, when used in combination with PD-1 blockade, completely eradicated all measurable tumors in preclinical models of ovarian cancer. Furthermore, the therapy achieved a 100% long-term survival rate in these models. Chief Scientific Officer Robert H. Pierce described the outcome as “complete tumor eradication and durable survival,” while Chief Executive Officer Sanjeev Luther characterized the data as “beyond expectations.”
Mechanism of Action and Development Plans
ERNA-101 is an allogeneic induced mesenchymal stem cell therapy designed as an off-the-shelf treatment option. It is engineered from reprogrammed adult cells to home in on tumors and secrete cytokines that modulate immune function. The goal is to convert immunologically “cold” tumors into targets for T cells, which are then activated by a PD-1 blocker that removes restraints on immune cells. The company noted that the combination therapy outperformed either agent alone, significantly reducing both tumor burden and ascites, a common complication in advanced ovarian cancer.
Ernexa intends to incorporate these findings into its development strategy as it advances ERNA-101 toward human trials for advanced ovarian cancer. The company has previously outlined plans to submit an investigational new drug application for ERNA-101 in the third quarter of 2026, targeting a Phase 1 first-in-human study in the fourth quarter.
Financial and Listing Status
The positive news comes on the heels of a corporate action aimed at maintaining Ernexa’s listing on the Nasdaq. The company recently completed a 1-for-25 reverse stock split, with shares trading on a split-adjusted basis starting Wednesday. The reverse split was implemented to restore compliance with Nasdaq’s $1 minimum bid price requirement. Despite the stock surge, Ernexa remains at a preclinical stage, with no approved products or human clinical data.
Market Context and Competitive Landscape
Platinum-resistant ovarian cancer represents a significant unmet medical need. The American Cancer Society estimates that approximately 21,010 women in the United States will be diagnosed with ovarian cancer in 2026, with around 12,450 deaths expected. The FDA defines platinum-resistant cases as those that progress within six months of platinum-based chemotherapy.
The competitive landscape has seen recent developments. In February, the FDA approved Merck’s Keytruda and Keytruda Qlex, each combined with paclitaxel (with or without bevacizumab), for select PD-L1-positive, platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer cases. In March, Corcept Therapeutics received approval for relacorilant plus nab-paclitaxel in certain adults with previously treated platinum-resistant disease.
Path Forward and Risks
While the preclinical data are encouraging, Ernexa faces substantial hurdles. The results are based on animal models, not human patients, and the company must navigate challenges in manufacturing, regulatory approval, and safety before initiating a Phase 1 trial to assess dosing, tolerability, and preliminary activity in humans.
Financial concerns also loom. As of December 31, 2025, Ernexa reported only $1.9 million in cash and an accumulated deficit of $245.6 million. The company’s annual report highlighted recurring losses and the need for additional working capital, casting substantial doubt on its ability to continue as a going concern.
Moving forward, the company’s immediate focus will be on transitioning ERNA-101 into clinical trials to validate whether the promising preclinical signals translate into human benefit.
